Recent news on Oxandrin

Savient Seems Set for a Success  -  May 22, 2007
Motley FoolPuricase would join Savient's Oxandrin -- which combats severe weight loss caused by infection, surgery or trauma -- on the market.

Savient Pharmaceuticals to Present at the Citigroup Healthcare ...  -  May 17, 2007
PharmaLive.com (press release),Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View

AIDS activists upset by dropped wasting drug  -  Apr 19, 2007
Bay Area Reporter,Their suspicions grew through this week as they learned that Savient Pharmaceuticals canceled its patient assistance program for Oxandrin, the second most

Savient Pharmaceuticals Reports Fourth Quarter and Year End 2006 ...  -  Mar 14, 2007
PharmaLive.com (press release),Mr. Clement continued, "The approval of Oxandrin(R) generics in December was an eventuality we anticipated and planned for, and while it will result in a

Savient Pharma Swings to 4Q Loss  -  Mar 13, 2007
Forbes,Savient Pharmaceuticals Inc. said Tuesday it swung to a fourth-quarter loss, hurt by generic competition for its Oxandrin product and higher

Savient Pharma swings to 4Q loss  -  Mar 13, 2007
ABCmoney.co.uk,EAST BRUNSWICK, NJ (AP) - Savient Pharmaceuticals Inc. said Tuesday it swung to a fourth-quarter loss, hurt by generic competition for its Oxandrin product

Savient Announces Completion Of Patient Enrollment In Phase 3 ...  -  Mar 13, 2007
Medical News Today (press release),Savient also markets Oxandrin®, oxandrolone tablets, (USP) C III in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further

Savient Pharmaceuticals to Hold Fourth Quarter and Year End ...  -  Mar 7, 2007
Business Wire (press release),Savient also manufactures and supplies Oxandrin ® (oxandrolone tablets, USP) CIII in the US Puricase ® is a registered trademark of Mountain View

Why Cramer is Wrong About Savient Pharmaceuticals  -  Feb 5, 2007
Seeking Alpha,His stated rationale includes great management, the drug Oxandrin, and Puricase for gout. I won’t try to assess management’s greatness or lack thereof,

Wall Street's Wish List  -  Jan 29, 2007
Motley FoolThis week, let's meet Savient, the small pharmaceutical company best known for its Oxandrin, a testosterone derivative used to promote weight gain in

Savient Disbands Oxandrin Sales Force  -  Jan 5, 2007
Houston Chronicle,EAST BRUNSWICK, NJ — Savient Pharmaceuticals Inc. said Friday it will eliminate the 19 people devoted to selling its Oxandrin weight gain drug now that it

Savient Disbands Oxandrin Sales Force  -  Jan 5, 2007
Forbes,Savient Pharmaceuticals Inc. said Friday it will eliminate the 19 people devoted to selling its Oxandrin weight gain drug now that it has launched a generic

Savient to discontinue Oxandrin field sales force  -  Jan 5, 2007
ReutersO: Quote, Profile , Research) said it will discontinue its 19-person field sales force for Oxandrin, its drug to treat involuntary weight loss,

Savient Pharmaceuticals Announces Launch of Authorized Generic of ...  -  Dec 29, 2006
PharmaLive.com (press release),The AB rated authorized generic of oxandrolone tablets will continue to meet all quality control standards of the Oxandrin(R) brand and will contain the

Savient Pharmaceuticals Restructures Commercial Operations ...  -  Jan 7, 2007
dBusinessNews Newark (press release),Oxandrin® is Savient’s oral anabolic agent for the treatment of involuntary weight loss, a frequent and sometimes life-threatening condition associated with

Thu: Amdocs and Comverse: Made for each other  -  Jan 15, 2007
Globes,First of all there is the experienced company management, second its drug Oxandrin, an adjunctive therapy to combat weight loss resulting from chronic

Friday's Health Winners & Losers  -  Dec 29, 2006
TheStreet.comThe court has only temporarily blocked sale of Sandoz and Upsher-Smith's generic oxandrolone, which Savient says infringes on its Oxandrin drug,

Market Report -- In Play (SVNT)  -  Dec 29, 2006
MSN MoneySavient Pharma announces launch of authorized generic of Oxandrin with Watson Pharmaceuticals Co announces that Watson Pharmaceuticals (WPI),

Savient files patent infringement lawsuit against Sandoz ...  -  Dec 28, 2006
Therapeutics Daily (subscription) (press release),These patents relate to various methods of using Savient's product Oxandrin (oxandrolone tablets, USP) CIII. Oxandrin is Savient's oral anabolic agent

Stocks May Gain On M&A Activity And Optimism Over Corporate ...  -  Jan 8, 2007
Trading Markets,Savient Pharma (SVNT | charts | news | PowerRating) could be in focus after it said it will eliminate 19 salespeople selling its Oxandrin weight gain drug.

Court Blocks Sale of Generic Oxandrin  -  Dec 13, 2006
Forbes,Oxandrin is an oral anabolic steroid agent that helps patients gain weight after weight loss from surgery, infection or severe trauma.

Savient restraining order vs Novartis, others lifted in Oxandrin ...  -  Dec 11, 2006
Forbes,ZURICH (AFX) - US drug maker Savient Pharmaceuticals Inc said a temporary restraining order blocking the sale of all generic versions of its Oxandrin drug

Savient suing Sandoz on Oxandrin patent  -  Dec 4, 2006
United Press International4 (UPI) -- US drug firm Savient said Monday it has filed a patent-infringement suit against Sandoz and Upsher-Smith Labs on the drug Oxandrin.

Savient Pharmaceuticals Announces Appellate Court Decision in ...  -  Dec 13, 2006
PharmaLive.com (press release),Oxandrin(R) is Savient's oral anabolic agent indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery,

Savient Pharmaceuticals Obtains Temporary Restraining Order in ...  -  Dec 5, 2006
PharmaLive.com (press release),Under the terms of the TRO, Savient also will not launch sales of the AB rated authorized generic of oxandrolone tablets, USP (C-III), an Oxandrin(R) brand

Savient Pharmaceuticals Files Patent Infringement Lawsuit  -  Dec 4, 2006
ag-IP-news Agency,According to a press release by the company, these patents relate to various methods of using Savient's product Oxandrin (oxandrolone tablets, USP) CIII.

Savient Restraining Order to Expire  -  Dec 11, 2006
Forbes,Savient Pharmaceuticals Inc. said Monday that its temporary restraining order blocking the sale of all generic versions of its drug Oxandrin will expire

Savient Restraining Order to Expire  -  Dec 11, 2006
Houston Chronicle,5 be lifted on Tuesday at 5:00 pm The temporary restraining order blocked sales of oxandrolone, the active ingredient in Savient's weight gain drug Oxandrin

Savient given generic restraining order  -  Dec 5, 2006
BusinessWeekOxandrin is an oral anabolic agent that helps patients gain weight after weight loss from surgery, infection or severe trauma.

Savient Pharmaceuticals Announces Appellate Court Decision in ...  -  Dec 14, 2006
ag-IP-news Agency,Savient also markets Oxandrin (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View Pharmaceuticals Inc.

Savient Cites Court Win  -  Dec 5, 2006
TheStreet.com...patents on the company's anabolic drug Oxandrin, which is used to promote weight gain following weight loss from extensive surgery, chronic infection,

Savient sues Sandoz, Upsher-Smith for patent infringement  -  Dec 4, 2006
ReutersOxandrin is indicated as an adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infection, or severe trauma.

Savient Pharmaceuticals (SVNT) Files Patent Infringement Suit ...  -  Dec 4, 2006
StreetInsider.com (subscription),These patents relate to various methods of using Savient's product Oxandrin CIII. Oxandrin is Savient's oral anabolic agent indicated as adjunctive therapy

Alliant Tech says $500M Army program at risk  -  Dec 6, 2006
Pioneer Press,Savient, based in East Brunswick, NJ, sued the companies Monday, claiming their copies of Oxandrin would infringe five Savient patents.

Wednesday's Health Winners & Losers  -  Dec 5, 2006
TheStreet.comCramer's Take) subsidiary Sandoz Pharmaceuticals and Upsher-Smith Laboratories for infringing a number of patents on its weight gain drug Oxandrin.

Savient Sues Sandoz, Upsher-Smith  -  Dec 4, 2006
Houston Chronicle,Savient said its suit alleges infringement of its patents on methods of using Oxandrin, an oral anabolic agent designed to help patients gain weight after

Northwest extends holiday fare sale  -  Dec 5, 2006
Pioneer Press,New Jersey-based Savient claims that Upsher-Smith and Novartis AG's Sandoz Pharmaceuticals infringed five patents on ways to use Oxandrin, prescribed for

UPDATE 1-Savient says court lifts sale ban on oxandrolone  -  Dec 11, 2006
ReutersN: Quote, Profile , Research) company, and Upsher-Smith for the infringement of five US patents related to various methods of using its steroid Oxandrin.

Savient says court lifts ban on oxandrolone sales  -  Dec 11, 2006
Reuters...against Sandoz and Upsher-Smith for infringement of a few US patents, related to various methods of using Savient's oral anabolic steroid Oxandrin.

Generic Oxandrolone Tablets Approved  -  Dec 7, 2006
Facts and Comparisons,...and for the relief of bone pain frequently accompanying osteoporosis. The medication is the generic equivalent of Oxandrin by Savient Pharmaceuticals.

Savient gets restraining order on oxandrolone sales by Sandoz ...  -  Dec 5, 2006
Forbes,...filed a lawsuit against Sandoz and Upsher-Smith for infringement of patents relating to various methods of using Savient's weight gain product Oxandrin.

Savient gets temporary restraining order in patent suit  -  Dec 5, 2006
Reuters...filed by Savient against Sandoz and Upsher-Smith for infringement of patents related to its oral anabolic steroid Oxandrin, Savient said in a statement.

Market Report -- In Play (SVNT)  -  Dec 4, 2006
MSN Money...and Upsher-Smith Laboratories for patent infringement related to various methods of using co's product Oxandrin, an oral anabolic agent indicated as

Public company news  -  Dec 10, 2006
Pioneer Press,...order that blocks Maple Grove-based Upsher-Smith Laboratories and Sandoz Pharmaceuticals from selling generic versions of Oxandrin, a weight-gain drug.

Stocks to Watch, Dec. 13: Cooper Cos., ADC Telecom and Martek  -  Dec 12, 2006
FOX NewsSavient Pharmaceuticals Inc. (SVNT) said a federal appellate court in Washington, DC, has temporarily banned all sales of generic Oxandrin,

Stocks to Watch: ADC Telecommunications, Fannie Mae, Google, Home ...  -  Dec 13, 2006
Minyanville.com,Savient Pharmaceuticals (SVNT) said a federal appellate court in Washington, DC, has temporarily banned all sales of generic Oxandrin, a weight treatment,

Savient Pharmaceuticals Announces Modification of Temporary ...  -  Dec 11, 2006
StreetInsider.com (subscription),...has directed and to determine the next actions and steps that may be available to us in defending our patent rights related to the use of Oxandrin®.

New Poll Shows the Extreme Pain of Gout is Detrimental to Quality ...  09 Nov 2006
Savient also markets Oxandrin® (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. ... -Yahoo! News (press release) Savient Pharmaceuticals Reports Third Quarter Financial Results  Oct 30, 2006
Net product sales increase of $4.8 million, up 43% over the prior year’s third quarter due to higher sales of Oxandrin ® of $5.8 million, up 57% for the ... -Business Wire (press release), Savient Pharmaceuticals Announces Preliminary Results of '' ...  Sep 12, 2006
Savient also markets Oxandrin(R) (oxandrolone, USP) in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. ... -Genetic Engineering News

Savient Pharmaceuticals to Present at ThinkEquity Partners LLC 4th ...  Sep 11, 2006
Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. ... -PharmaLive.com

Savient Pharmaceuticals to Present at Roth Capital Partners 2006 ...  Aug 31, 2006
...initial focus in rheumatology. Savient markets itsproduct Oxandrin(R) (oxandrolone, USP) in the United States. Puricaseis a registered ... -Finanzen.net

ROTH New York Conference 2006 Presenter Profiles  Sep 1, 2006
Savient markets its product Oxandrin(r) (oxandrolone, USP) in the United States. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. ... -Business Wire

Savient Pharmaceuticals Announces Appellate Court Decision in ...  -  12 Dec 2006
American Digital Networks (press release),Oxandrin(R) is Savient's oral anabolic agent indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery,

Stocks to Watch, Dec. 13: Cooper Cos., ADC Telecom and Martek  -  12 Dec 2006
FOX NewsSavient Pharmaceuticals Inc. (SVNT) said a federal appellate court in Washington, DC, has temporarily banned all sales of generic Oxandrin,

Savient Pharmaceuticals Obtains Temporary Restraining Order in ...  -  Dec 5, 2006
PharmaLive.com (press release),Under the terms of the TRO, Savient also will not launch sales of the AB rated authorized generic of oxandrolone tablets, USP (C-III), an Oxandrin(R) brand

Patent Law - Savient Pharmaceuticals Files Patent Infringement ...  -  Dec 4, 2006
Lawfuel (press release),Oxandrin® is Savient’s oral anabolic agent indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery,

Savient Pharmaceuticals Files Patent Infringement Lawsuit  -  Dec 4, 2006
ag-IP-news Agency,According to a press release by the company, these patents relate to various methods of using Savient's product Oxandrin (oxandrolone tablets, USP) CIII.

Savient given generic restraining order  -  Dec 5, 2006
BusinessWeekOxandrin is an oral anabolic agent that helps patients gain weight after weight loss from surgery, infection or severe trauma.

Savient Cites Court Win  -  Dec 5, 2006
TheStreet.com...patents on the company's anabolic drug Oxandrin, which is used to promote weight gain following weight loss from extensive surgery, chronic infection,

Alliant Tech says $500M Army program at risk  -  Dec 6, 2006
Pioneer Press,Savient, based in East Brunswick, NJ, sued the companies Monday, claiming their copies of Oxandrin would infringe five Savient patents.

Savient sues Sandoz, Upsher-Smith for patent infringement  -  Dec 4, 2006
ReutersOxandrin is indicated as an adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infection, or severe trauma.

Savient Pharmaceuticals (SVNT) Files Patent Infringement Suit ...  -  Dec 4, 2006
StreetInsider.com (subscription),These patents relate to various methods of using Savient's product Oxandrin CIII. Oxandrin is Savient's oral anabolic agent indicated as adjunctive therapy

Wednesday's Health Winners & Losers  -  Dec 5, 2006
TheStreet.comCramer's Take) subsidiary Sandoz Pharmaceuticals and Upsher-Smith Laboratories for infringing a number of patents on its weight gain drug Oxandrin.

Generic Oxandrolone Tablets Approved  -  Dec 7, 2006
Facts and Comparisons,...and for the relief of bone pain frequently accompanying osteoporosis. The medication is the generic equivalent of Oxandrin by Savient Pharmaceuticals.

Northwest extends holiday fare sale  -  Dec 5, 2006
Pioneer Press,New Jersey-based Savient claims that Upsher-Smith and Novartis AG's Sandoz Pharmaceuticals infringed five patents on ways to use Oxandrin, prescribed for

Savient Sues Sandoz, Upsher-Smith  -  Dec 4, 2006
Houston Chronicle,Savient said its suit alleges infringement of its patents on methods of using Oxandrin, an oral anabolic agent designed to help patients gain weight after

Savient gets restraining order on oxandrolone sales by Sandoz ...  -  Dec 5, 2006
Forbes,...filed a lawsuit against Sandoz and Upsher-Smith for infringement of patents relating to various methods of using Savient's weight gain product Oxandrin.

Savient gets temporary restraining order in patent suit  -  Dec 5, 2006
Reuters...filed by Savient against Sandoz and Upsher-Smith for infringement of patents related to its oral anabolic steroid Oxandrin, Savient said in a statement.

Market Report -- In Play (SVNT)  -  Dec 4, 2006
MSN Money...and Upsher-Smith Laboratories for patent infringement related to various methods of using co's product Oxandrin, an oral anabolic agent indicated as

Public company news  -  Dec 10, 2006
Pioneer Press,...order that blocks Maple Grove-based Upsher-Smith Laboratories and Sandoz Pharmaceuticals from selling generic versions of Oxandrin, a weight-gain drug.

Savient Pharmaceuticals to Present at Lazard Capital Markets Third ...  -  Nov 22, 2006
PharmaLive.com (press release),Savient also markets Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further

Savient Pharmaceuticals Commences Offer to Repurchase up to 10 ...  Aug 14, 2006
R) drug candidate currently in phase 3 clinical trials for treatment-failure gout, and the possible timing and effect of a generic version of Oxandrin(R).". ... -Business New Jersey (subscription)

Savient Pharmaceuticals Reports Second Quarter and First Half 2006 ...  Aug 8, 2006
...million as compared with $22.6 million for the second quarter of 2005, an increase of $1.4 million, or 6% due primarily to product sales of Oxandrin(R) in the ... -Genetic Engineering News

Savient Pharmaceuticals Reports Second Quarter and First Half 2006 ...  Aug 8, 2006
Sales of Oxandrin were $13.8 million for the second quarter of2006 compared with $11.4 million for the second quarter of 2005, anincrease of $2.4 million, or 21 ... -Finanzen.net

Savient Pharmaceuticals Completes Sale of Rosemont Pharmaceuticals ...  Aug 4, 2006
...initial focus in rheumatology. Savient markets itsproduct Oxandrin(R) (oxandrolone, USP) in the United States. Puricaseis a registered ... -Die Welt

Savient Pharmaceuticals Completes Sale of Rosemont Pharmaceuticals ...  Aug 4, 2006
Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. ... -PharmaLive.com

Savient Pharma Swings To Q2 Profit - Upda  Aug 8, 2006
On a segmental basis, sales of Oxandrin for the second quarter rose 21% to $13.8 million from $11.4 million in the previous-year quarter. ... -Trading Markets

Savient Pharma Shares Rise 11% On 2Q Results  Aug 9, 2006
Revenue rose 6.1% to $24 million from $22.6 million, driven by improved sales of Oxandrin in the US, and oral liquid pharmaceutical products in the company's ... -Easy Bourse (Communiqués de presse)

Savient Pharmaceuticals Commences Offer to Repurchase up to 10 ...  Aug 14, 2006
...product candidates, difficulties of expandingSavient's product portfolio through in-licensing, introduction ofgeneric competition for Oxandrin, fluctuations in ... -Finanzen.net

Savient Pharmaceuticals to Report Second Quarter 2006 Financial ...  Aug 2, 2006
...focus in rheumatology. Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary ... -Genetic Engineering News

Savient Pharmaceuticals to Report Second Quarter 2006 Financial ...  Aug 2, 2006
...focus in rheumatology. Savient markets itsproduct Oxandrin(R) (oxandrolone, USP) in the United States. TheCompany's subsidiary, Rosemont ... -Finanzen.net

Biolight unit OBEcure to develop weight loss treatment  Jul 20, 2006
...in biotechnology. The company's treatment for involuntary weight loss, Oxandrin, is still one of its flagship drugs. OBEcure's recently ... -Globes

Savient's Puricase(R) (PEG-uricase) Phase 2 Results Show Powerful ...  Jun 22, 2006
...focus in rheumatology. Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary ... -Genetic Engineering News

Savient's Puricase(R) (PEG-uricase) Phase 2 Results Show Powerful ...  Jun 22, 2006
...focus in rheumatology. Savient markets itsproduct Oxandrin(R) (oxandrolone, USP) in the United States. TheCompany's subsidiary, Rosemont ... -Finanzen.net

Savient Appoints Chief Financial Officer and Treasurer  Jul 6, 2006
...initial focus inrheumatology. Savient markets its product Oxandrin(R) (oxandrolone,USP) in the United States. The Company's subsidiary ... -Finanzen.net



Savient Reports Results for First Quarter 2006  May 11, 2006
Net product sales were $18.9 million compared to $20.8 million in 2005, a decrease of 9%, attributable to the decrease in Oxandrin(R) sales and the sale of ... - Finanzen.net

Savient Receives FDA Final Approval for Puricase (PEG-uricase) ...  May 3, 2006
...initial focus inrheumatology. Savient markets its product Oxandrin(R) (oxandrolone,USP) in the United States. The Company's subsidiary ... - Finanzen.net

Cytogen and Savient Finalize Exclusive Distribution Agreement for ...  Apr 24, 2006
...initial focus in rheumatology. Savient markets its product Oxandrin® (oxandrolone, USP) in the United States. The Company's subsidiary ... - Yahoo! News





Savient Pharmaceuticals, Inc. Announces Proposed Changes to Board ...  Apr 10, 2006
...initial focus inrheumatology. Savient markets its product Oxandrin(R) (oxandrolone,USP) in the United States. The Company's subsidiary ... - Finanzen.net

Savient Pharma Posts Full Year Profit  Mar 30, 2006
Revenue fell 9 percent to $87.8 million from $96.4 million last year on lower sales of Oxandrin, a drug to promote weight gain after surgery, and testosterone ... - Houston Chronicle

Savient Reports Results for the Full Year 2005  Mar 30, 2006
...and Drugs not approve any Abbreviated New Drug Application (ANDA) for generic oral products containing oxandrolone, the active molecule in Oxandrin(R), prior ... - Genetic Engineering News

Steroid use can raise bad cholesterol  Mar 8, 2006
...should stop taking the drug. The study received funding from Savient Pharmaceuticals Inc., which markets oxandrolone as Oxandrin. - MSNBC

Steroid useful in HIV, dangerous to the healthy  Mar 8, 2006
...taking the drug. The study received funding from Savient Pharmaceuticals Inc., which markets oxandrolone as Oxandrin. SOURCE: Journal ... - The Westfall Weekly News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional